NCT06256419Recruiting
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University
Source: ClinicalTrials.gov · Last updated 18 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months. The objective of this study is to investigate the influence of T2DM susceptibility gene polymorphisms (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) on the efficacy of GLP-1 RA (exenatide, liraglutide, etc.), to identify the variables that can predict the efficacy of GLP-1 RA, and to evaluate the weight of these variables on the efficacy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 5 Feb 2024
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Jan 2028
- Lead sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Diseases
- Type 2 diabetes
- NCT number
- NCT06256419
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 1 Jan 2024 to the primary completion date, 31 Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months
- those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy.
Other illness
- Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis
Who the study is looking for
- a diagnosis of T2DM
- a body mass index (BMI) of 20-35 kg/m2
- an HbA1c of 7.0%-12%, an age of 25-70 years
- required data available at baseline and 6 months after GLP-1RA therapy.
Age in the registry: 25 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China, Jiangsu, Department of Endocrinology Coordinator of this site? Confirm its status | Xuzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.